Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth

Abstract

Physician who prescribe 17-OHP-C should be aware not only of the potential surrogate efficacy from the randomised clinical trial, but also of the survival curve presented by the FDA, the conclusion of the FDA Advisory Panel which found no improvement in infant outcome and a concern over the miscarriages and finaly the animal toxicology data with signals for fetal toxicity.

Keywords

• 17-OHP-C
• preterm birth